Summary
For decades, moderate-to-severe atopic dermatitis (AD) was managed with topical steroids, calcineurin inhibitors, and broad immunosuppressants, until targeted biologics transformed care.
Two biologics dominate: DUPIXENT (dupilumab) by Sanofi/Regeneron and ADBRY (tralokinumab) by LEO Pharma; both target the Type 2 (Th2) immune pathway but differ in mechanism, approval timing, and market position.
Several promising competitors, such as LEO Pharma’s Temtokibart, Connect Biopharma’s Rademikibart (CBP-201), UNION Therapeutics’ Orismilast, Biosion and Aclaris Therapeutics’ Bosakitug (BSI-045B), Roche/Genentech’s Afimkibart (RG6631), Nektar Therapeutics’ Re...
